Sobi Buys Arthrosi to Broaden Gout Franchise and Push Into Chronic Inflammation
Swedish orphan-drug specialist Sobi has agreed to acquire Arthrosi, a privately held biotech focused on next-generation gout therapies
Merger & Acquisitions
Novo Nordisk Secures Breakthrough MASP-3 Asset in $2.1B Omeros Deal
Omeros has finalized the handoff of its clinical-stage MASP-3 monoclonal antibody zaltenibart (OMS906) to Novo Nordisk, closing a transaction that delivers immediate liquidity, removes near-term financing overhangs, and validates a complement-pathway mechanism increasingly viewed as one of the next competitive frontiers in immunology. The deal, first signed in mid-October, brings Omeros $240 million at closing … Read more
GE HealthCare to Acquire Intelerad for $2.3B to Build a Cloud-First Enterprise Imaging Platform
GE HealthCare to Acquire Intelerad for $2.3B, Advancing a Cloud-First Imaging Strategy and Expanding Its Reach Across Ambulatory and Hospital Markets GE HealthCare has signed an agreement to acquire Intelerad for $2.3 billion in cash, a move that significantly accelerates the company’s cloud-first transformation and strengthens its position across enterprise imaging in both hospital and … Read more
Alkermes Raises Avadel Acquisition Offer to $2.37B, Outmaneuvering Lundbeck With Superior CVR Terms
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
J&J’s $3B Halda Deal Sets Up $50B Oncology Push
J&J is acquiring Halda Therapeutics for $3.05B, gaining a precision prostate cancer therapy and a breakthrough induced-proximity platform.
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025
The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more
Cidara Therapeutics Stock sky-Rockets on $9B Merck buyout
Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
Lilly Doubles Down on Genetic Medicines with $1.6B RNAi and Gene Therapy Alliances
Eli Lilly has signed back-to-back collaborations with SanegeneBio and MeiraGTx, advancing its genetic medicine portfolio across RNA interference and ophthalmic gene therapy. Together, the agreements deepen Lilly’s position in next-generation RNA- and DNA-based therapeutics.
Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk
Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s … Read more
Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.